• Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
  • Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.
AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy
Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy
Two New Studies Are Rewriting the Rules of Psychedelic Drug Development
Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative
Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward
Delix Therapeutics Reports Strong Phase Ib Results
Childhood Trauma’s Role in Men’s Substance Use Disorders
Human-Centered AI in Healthcare
Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up
Shop

Honoring Roland Griffiths: Psychedelic Pioneer

Microdose by Microdose
October 17, 2023
in Culture
Reading Time: 2 mins read
A A
Honoring Roland Griffiths: Psychedelic Pioneer

The psychedelic medicine community has lost one of its great figures as Dr. Roland Griffiths has passed away.

Roland Griffiths, Ph.D., was a Professor of Psychiatry and Neurosciences at the Johns Hopkins University School of Medicine, and founding Director of the Johns Hopkins Center on Psychedelic and Consciousness Research. He was a world-renowned psychopharmacologist whose research helped to revive interest in the therapeutic potential of psychedelic drugs.

Dr. Griffiths had been battling terminal cancer for the last few years, yet still managed to keep up his work and advocacy, becoming an even more public and inspiring figure as he moved through the final stages of his journey.

 

[bsa_pro_ad_space id=2]
ADVERTISEMENT

For a deeper look at Dr. Griffiths’ view on his life and work, read this piece from Johns Hopkins, told in Roland’s own words:

ROLAND GRIFFITHS REFLECTS ON SCIENTIFIC CURIOSITY, GRATITUDE, AND COMING TO TERMS WITH A TERMINAL ILLNESS

 

Continue on your trip...

Childhood Trauma’s Role in Men’s Substance Use Disorders

Human-Centered AI in Healthcare

After the Billion-Dollar Psychedelic Bet: Who’s Next for Big Pharma?

Roland Griffiths: Life & Work

Griffiths was born in Glen Cove, New York, on July 19, 1946. He earned his undergraduate degree from Occidental College and his Doctor of Philosophy from the University of Minnesota in psychopharmacology in 1972. After completing his postdoctoral training, he joined the faculty of the Johns Hopkins University School of Medicine.

Griffiths’ early research focused on the behavioral and subjective effects of sedative-hypnotics, caffeine, and other mood-altering drugs. In 1999, he initiated a research program investigating the effects of the classic psychedelic psilocybin. His research has found that psilocybin can be safely administered to healthy volunteers and can produce profound mystical and spiritual experiences. Griffiths’ work has also shown that psilocybin can be effective in treating a variety of mental health conditions, including depression, anxiety, and post-traumatic stress disorder (PTSD).

In addition to his research on psilocybin, Griffiths has also studied other psychedelic drugs, such as LSD and ayahuasca. He has also published extensively on the history of psychedelic research and the ethical implications of using psychedelics in therapy.

Griffiths’ work has had a major impact on the field of psychedelic research. He is considered one of the leading experts in the field, and his research has helped to pave the way for the renewed interest in psychedelic therapy that is currently underway.

His research has been largely supported by grants from the National Institute on Health and he is the author of over 400 journal articles and book chapters, and has trained more than 50 postdoctoral research fellows. He has been a consultant to the National Institutes of Health, to numerous pharmaceutical companies in the development of new psychotropic drugs, and as a member of the Expert Advisory Panel on Drug Dependence for the World Health Organization.

 

Watch this inspiring video of Dr. Griffiths talking to Oprah about his life, his work, and how he’s handling his final chapter with grace.

Lasix Online Pharmacy Sale

 

[bsa_pro_ad_space id=2]
ADVERTISEMENT
Microdose

Microdose

At our core, we champion integrity, diversity, and objectivity, providing trusted content that unites a wide array of experts and fosters unbiased opinions, ultimately empowering the psychedelic medicine community to flourish and make a positive impact on the world.

Next Post
Spravato Sales Lead J&J Third Quarter Results

Spravato Sales Lead J&J Third Quarter Results

Who do you think will be first to successfully develop a psychedelic drug?
This field is for validation purposes and should be left unchanged.

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

ADVERTISEMENT

Follow us on social

Microdose is your guide to psychedelics. Our mission is to shift the world’s perception of psychedelic medicine.

Read the News
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
Online Courses
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
Subscribe for Exclusive Updates

Terms & Conditions / Privacy Policy

© 2026 MD Media Inc. All rights reserved. The information provided on this website does not, and is not intended to, constitute financial, legal or medical advice. All information, content, and materials available on this site are for general educational and informational purposes only.

WordPress Ads
No Result
View All Result
  • Landing Page
  • Buy JNews
  • Support Forum
  • Contact Us

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.